Tuesday, March 31, 2020

Multi-Lingual Support From the Global MediXchange of Combating COVID-19 (GMCC) Programme to Further Enable Sharing Among Medical Personnel Worldwide



HANGZHOU, China-Thursday 26 March 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Over 440 medical institutions from 104 countries and regions have applied to learn and share experiences in battling COVID-19 through the International Medical Expert Communication Platform. The Handbook of COVID-19 Prevention and Treatment is now available in seven languages with more to come.

The platform, a centerpiece of the Global MediXchange for Combating COVID-19 (GMCC) program, was jointly established by the Jack Ma Foundation and Alibaba Foundation. It is designed for medical experts around the world to communicate seamlessly with each other to share their invaluable experience of fighting coronavirus disease 2019 (COVID-19) and to ask and answer each other’s questions. To date, the most applications have come in thus far from medical institutions in the U.S, Turkey, the U.K., Pakistan, Spain and Germany.

Medical staff need to apply and be approved to join the platform. Once they’re accepted, they’re free to participate in individual or group discussions and sessions.

“Knowledge is power! We launched an online platform for doctors and nurses around the world to exchange ideas, lessons and know-how to fight the virus. We welcome all hospitals to join Chinese hospitals on this open platform https://covid-19.alibabacloud.com. One world, one fight!" Jack Ma wrote in a tweet Wednesday.

Tapping Alibaba Group’s DingTalk messaging and communications functions, the digital platform provides free audio and video conference functionality, along with live broadcast functions for more-complex scenarios. Medical workers from different countries can choose to communicate with their fellow doctors individually, or they can participate in live-sharing group sessions to interact with multiple participants, using real-time artificial intelligence translation to overcome communication barriers. The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), for example, has been using the platform to share their valuable experience with 92 medical institutions from 44 countries and regions.

A playback function allows further sharing or posting on official websites for consumption anytime – and for those who can’t join the live broadcasts due to the time difference or if they are occupied by their duties.

To date, the International Medical Expert Communication Platform has attracted numerous Chinese medical institutions, including Zhongnan Hospital of Wuhan University (Wuhan Leishenshan Hospital), The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), and others.

Through video conferencing and AI translation from and into 11 languages (Arabic, Chinese, English, French, Indonesian, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), the platform aims to build a virtual community.

DingTalk, which powers this platform, has also been tabbed by UNESCO as facilitating distance learning during the coronavirus outbreak.

Also as part of the GMCC programme, the Handbook of COVID-19 Prevention and Treatment, authored by The First Affiliated Hospital, Zhejiang University School of Medicine and compiled according to clinical experience, is now available at no cost in Chinese, English, French, Italian, Japanese, Turkish and Spanish. This handbook provides comprehensive guidelines and best practices by China's top experts for coping with COVID-19. More languages will be added soon, as the GMCC programme continues to launch more anti-epidemic resources and provide more practical suggestions and references for medical staff worldwide.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005799/en/

Contacts

Luica Mak
+44-7905471332
luica.mak@alibaba-inc.com

Crystal Liu
+86 18578497650
Crystal.liu@alibaba-inc.com

Permalink : https://www.aetoswire.com/news/multi-lingual-support-from-the-global-medixchange-of-combating-covid-19-gmcc-programme-to-further-enable-sharing-among-medical-personnel-worldwide/en

TruDoc 24x7 DHA licensed doctors provide convenient and round-the-clock teleconsultations to help ease panic surrounding COVID-19



Dubai, United Arab Emirates, -Monday 30 March 2020 [ AETOS Wire ]

TruDoc Healthcare has risen to the occasion in the wake of the COVID-19 outbreak and has been providing patients with appropriate medical management and advice quickly and conveniently given the present medical situation. It is already experiencing an upsurge in audio and video consultations related to respiratory tract infections and other similar illnesses. TruDoc 24x7 is at the forefront of helping people stay informed with the latest information on the COVID-19, warning signs and symptoms and preventive measures to combat this pandemic.

Any individual can call in and speak to a doctor from the convenience of their home or office, anytime and anywhere in the world to check for their health queries. If they are concerned about any symptoms related to COVID-19 or looking for comprehensive information on the illness, typical symptoms and precautions to be followed, they can video or audio call and get truthful and unbiased medical diagnoses from highly trained, DHA licensed doctors rather than relying on unreliable information.

As per Dubai Health Authority guidelines, given the current scenario, it is best to avoid close contact with people and public assemblies and congregations, among other preventive measures. Also, If any person has recently travelled to any country or city which has reported COVID-19 cases or been in contact with someone who has made such travel, and has been experiencing any of the symptoms like fever, cough and difficulty in breathing, it is highly advised that he/she seek medical attention.

TruDoc 24x7 upholds the regulatory bodies’ mandate and urges patients to avoid overcrowded hospitals and facilities and rather, utilize immediate video consultations with doctors from the comfort of their home or workplace and save themselves from unnecessary trips to the hospital and thereby, hospital acquired infections. Our experienced physicians who are highly trained and DHA licensed on telehealth practices are also able to request lab tests as well as issue electronic prescriptions for acute and chronic conditions and ensure delivery of medications, wherever applicable.

Dr. Ebtihal Darwish, our Chief Medical Officer; Dr. Veena Pillai, our Senior Medical Director and Dr. Yosef Alsaieq, our COVID-19 Medical Director are all strong advocate of 24x7 access to doctors in today’s digital age as they find this as the need of the hour. Our full-time team of licensed doctors, wellness advisors and case managers are available 24x7 to support people during the coronavirus pandemic. As the leading telemedicine provider in the UAE for the past 8 years and with 3.4 million paid subscribers, we ensure that we continue “Doing the Right Thing”. Our doctors tell patients the truth about what they need, not what they can afford.

TruDoc 24x7 brings the perfect blend of technology and medical expertise to its members by providing a one-of-a-kind 24x7 Population Health Management solution for individuals with acute and chronic conditions and people who need to achieve a healthier lifestyle.

Contacts

SAHARA Communications

Noor Abdelhafez, Account Executive, +97143298996, +971506946519

n.hafiz@saharapr.com / www.saharagcc.com  


Permalink : https://www.aetoswire.com/news/trudoc-24x7-dha-licensed-doctors-provide-convenient-and-round-the-clock-teleconsultations-to-help-ease-panic-surrounding-covid-19/en

Monday, March 30, 2020

C3.ai, Microsoft, and Leading Universities Launch C3.ai Digital Transformation Institute

 C3.ai, Microsoft Corporation, the University of Illinois at Urbana-Champaign; the University of California, Berkeley; Princeton University; the University of Chicago; the Massachusetts Institute of Technology; and Carnegie Mellon University form the new C3.ai Digital Transformation Institute

First call for proposals published – AI Techniques to Mitigate Pandemic

Institute to accelerate AI innovation among scientific communities to bring greater advocacy, invention, collaboration, and academic rigor to scaling digital transformation

REDWOOD CITY, Calif. & REDMOND, Wash. & URBANA-CHAMPAIGN, Ill. & BERKELEY, Calif.-Monday 30 March 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- C3.ai, Microsoft Corporation, the University of Illinois at Urbana-Champaign (UIUC), the University of California, Berkeley, Princeton University, the University of Chicago, the Massachusetts Institute of Technology, Carnegie Mellon University, and the National Center for Supercomputing Applications at UIUC announced two major initiatives:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200326005334/en/

    C3.ai Digital Transformation Institute (C3.ai DTI), a research consortium dedicated to accelerating the application of artificial intelligence to speed the pace of digital transformation in business, government, and society. Jointly managed by UC Berkeley and UIUC, C3.ai DTI will sponsor and fund world-leading scientists in a coordinated effort to advance the digital transformation of business, government, and society.
    C3.ai DTI First Call for Research Proposals: C3.ai DTI invites scholars, developers, and researchers to embrace the challenge of abating COVID-19 and advance the knowledge, science, and technologies for mitigating future pandemics using AI. This is the first in what will be a series of bi-annual calls for Digital Transformation research proposals.

“The C3.ai Digital Transformation Institute is a consortium of leading scientists, researchers, innovators, and executives from academia and industry, joining forces to accelerate the social and economic benefits of digital transformation,” said Thomas M. Siebel, CEO of C3.ai. “We have the opportunity through public-private partnership to change the course of a global pandemic,” Siebel continued. “I cannot imagine a more important use of AI.”

Immediate Call for Proposals: AI Techniques to Mitigate Pandemic

Topics for Research Awards may include but are not limited to the following:

    Applying machine learning and other AI methods to mitigate the spread of the COVID-19 pandemic
    Genome-specific COVID-19 medical protocols, including precision medicine of host responses
    Biomedical informatics methods for drug design and repurposing
    Design and sharing of clinical trials for collecting data on medications, therapies, and interventions
    Modeling, simulation, and prediction for understanding COVID-19 propagation and efficacy of interventions
    Logistics and optimization analysis for design of public health strategies and interventions
    Rigorous approaches to designing sampling and testing strategies
    Data analytics for COVID-19 research harnessing private and sensitive data
    Improving societal resilience in response to the spread of the COVID-19 pandemic
    Broader efforts in biomedicine, infectious disease modeling, response logistics and optimization, public health efforts, tools, and methodologies around the containment of rising infectious diseases and response to pandemics, so as to be better prepared for future infectious diseases

The first call for proposals is open now, with a deadline of May 1, 2020. Researchers are invited to learn more about C3.ai DTI and how to submit their proposals for consideration at C3DTI.ai. Selected proposals will be announced by June 1, 2020.

Up to $5.8 million in awards will be funded from this first call, ranging from $100,000 to $500,000 each. In addition to cash awards, C3.ai DTI recipients will be provided with significant cloud computing, supercomputing, data access, and AI software resources and technical support provided by Microsoft and C3.ai. This will include unlimited use of the C3 AI Suite and access to the Microsoft Azure cloud platform and access to the Blue Waters supercomputer at the National Center for Supercomputing Applications (NCSA) at UIUC.

“We are collecting a massive amount of data about MERS, SARS, and now COVID-19,” said Condoleezza Rice, former US Secretary of State. “We have a unique opportunity before us to apply the new sciences of AI and digital transformation to learn from these data how we can better manage these phenomena and avert the worst outcomes for humanity,” Rice continued. “I can think of no work more important and no response more cogent and timely than this important public-private partnership.”

“We’re excited about the C3.ai Digital Transformation Institute and are happy to join on a shared mission to accelerate research at these eminent research institutions,” said Eric Horvitz, Chief Scientist at Microsoft and C3.ai DTI Advisory Board Member. “As we launch this exciting private-public partnership, we’re enthusiastic about aiming the broader goals of the Institute at urgent challenges with the COVID-19 pandemic, as well as on longer-term research that could help to minimize future pandemics.”

"At UC Berkeley, we are thrilled to help co-lead this important endeavor to establish and advance the science of digital transformation at the nexus of machine learning, IoT, and cloud computing,” said Carol Christ, Chancellor, UC Berkeley. “We believe this Institute has the potential to make tremendous contributions by including ethics, new business models, and public policy to the technologies for transforming societal scale systems globally."

“The C3.ai Digital Transformation Institute, with its vision of cross-institutional and multi-disciplinary collaboration, represents an exciting model to help accelerate innovation in this important new field of study,” said Robert J. Jones, Chancellor of the University of Illinois at Urbana-Champaign. “At this time of a global health crisis, the Institute’s initial research focus will be on applying AI to mitigate the COVID-19 pandemic and to learn from it how to protect the world from future pandemics. C3.ai DTI is an important addition to the world’s fight against this disease and a powerful new resource in developing solutions to all societal challenges.”

“Together with the other C3.ai Digital Transformation Institute partners, we look forward to creating a powerful ecosystem of scholars and educators committed to applying 21st century technologies to the benefit of all,” said Chris Eisgruber, President of Princeton University. “This public-private partnership with innovators like C3.ai and Microsoft, providing support to world-class researchers across a range of disciplines, promises to bring rapid innovation to an exciting new frontier.”

“By strongly supporting multidisciplinary research and multi-institution projects, the C3.ai DTI represents a new avenue to develop breakthrough scientific results with a positive impact on society at a time of great need,” said Robert Zimmer, President of the University of Chicago. “I’m very pleased that the University of Chicago is part of this formidable collaboration between academia and industry to lead crucial innovation with great purpose and urgency.”

“The vision of C3.ai DTI is driven by the recognition of digital transformation as both a science as well as a scientific imperative for this pivotal time, applicable to every sector of our economy across the public and private sectors, including in healthcare, education, and public health,” said Farnam Jahanian, President of Carnegie Mellon University. “We are excited to participate in building out the Institute’s structure, program and further alliances. This is just the beginning of an ambitious journey that can have enormous positive impact on the world.”

"At MIT, we share the commitment of C3.ai DTI to advancing the frontiers of AI, cybersecurity and related fields while building into every inquiry a deep concern for ethics, privacy, equity and the public interest,” said Rafael Reif, President of the Massachusetts Institute of Technology. “At this moment of national emergency, we are proud to be part of this intensive effort to apply these sophisticated tools to better analyze the COVID-19 epidemic and devise effective ways to stop it. We look forward to accelerating this work both by collaborating with the companies and institutions in the initiative, and by drawing on the frontline experience and clinical data of our colleagues in Boston's world-class hospitals."

Building Community

At the heart of C3.ai DTI will be the constant flow of new ideas and expertise provided by ongoing research, visiting professors and research scholars, and faculty and scholars in residence, many of whom will come from beyond the member institutions. This rich ecosystem will form the foundational structure of a new Science of Digital Transformation.

“This is about global innovation based on multinational collaboration to accelerate the positive impact of AI by providing researchers access to real world data and to massive resources,” said Jim Snabe, Chairman, Siemens. “This is exactly the kind of multinational public-private partnership that is required to address this critical issue.”

“I could not be more proud of our association with C3.ai and Microsoft,” said Lorenzo Simonelli, CEO of Baker Hughes. “This is exactly the kind of leadership that is required to bring together the best of us to address this critical need.”

“We are at war and we must win it! Using all means,” said Jacques Attali, French statesman. “This great project will organize global scientific collaboration for accelerating the social impact of AI, and help to win this war, using new weapons, for the best of mankind.”

“In these difficult times, we need – now more than ever – to join our forces with scholars, innovators, and industry experts to propose solutions to complex problems. I am convinced that digital, data science and AI are a key answer,” said Gwenaëlle Avice-Huet, Executive Vice President of ENGIE. “The C3.ai Digital Transformation Institute is a perfect example of what we can do together to make the world better.”

Establishing the New Science of Digital Transformation

C3.ai DTI will focus its research on AI, Machine Learning, IoT, Big Data Analytics, human factors, organizational behavior, ethics, and public policy. The Institute will support the development of ML algorithms, data security, and cybersecurity techniques. C3.ai DTI research will analyze new business operation models, develop methods of implementing organizational change management and protecting privacy, and amplify the dialogue around the ethics and public policy of AI.

C3.ai Digital Transformation Institute is a Research Initiative that Includes:

    Research Awards: Up to 26 cash awards annually, ranging from $100,000 to $500,000 each
    Computing Resources: Access to free Azure Cloud and C3 AI Suite resources
    Visiting Professors & Research Scientists: $750,000 per year to support C3.ai DTI Visiting Scholars
    Curriculum Development: Annual awards to faculty at member institutions to develop curricula that teach the emerging field of Digital Transformation Science
    Data Analytics Platform: C3.ai DTI will host an elastic cloud, big data, development, and operating platform, including the C3 AI Suite hosted on Microsoft Azure for the purpose of supporting C3.ai DTI research, curriculum development, and teaching.
    Educational Program: $750,000 a year to support an annual conference, annual report, newsletters, published research, and website
    Industry Alignment: C3.ai DTI Industry Partners will be established to assure the institute’s operations are aligned to the needs of the private sector.
    Open Source: C3.ai DTI will strongly favor proposals that promise to publish their research in the public domain.

To support the Institute, C3.ai will provide C3.ai DTI $57,250,000 in cash contributions over the first five years of operation. C3.ai and Microsoft will contribute an additional $310 million in-kind, including use of the C3 AI Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.

To learn more about C3.ai DTI’s program, award opportunities, and call for proposals, please visit C3DTI.ai.

About C3.ai Digital Transformation Institute

C3.ai Digital Transformation Institute represents an innovative vision to take AI, ML, IoT, and big data research in a consortium model to a level that cannot be achieved at any one institution alone. Jointly managed and hosted by the University of California, Berkeley and the University of Illinois at Urbana-Champaign, C3.ai DTI will attract the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society, and establish the new Science of the Digital Transformation of Societal Systems.

About C3.ai

C3.ai is a leading AI software provider for accelerating digital transformation. C3.ai delivers the C3 AI Suite for developing, deploying, and operating large-scale AI, predictive analytics, and IoT applications in addition to an increasingly broad portfolio of turn-key AI applications. The core of the C3.ai offering is a revolutionary, model-driven AI architecture that dramatically enhances data science and application development. Learn more at: www.c3.ai.

About Microsoft

Microsoft (Nasdaq “MSFT” @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.

About University of Illinois at Urbana-Champaign

The University of Illinois at Urbana-Champaign is a public land-grant research university founded in 1867 and dedicated to building upon a tradition of excellence in education, research, public engagement and economic development. The university pioneers innovative research that tackles global problems and expands the human experience. Illinois faculty, staff and alumni have been leading the way in digital transformation from the invention of the transistor to the birth of the graphical internet browser to high performance computing to the new revolution in data sciences and analytics.

About University of California, Berkeley

UC Berkeley is the world’s premier public university with a mission to excel in teaching, research and public service. This longstanding mission has led to the university's distinguished record of Nobel-level scholarship, constant innovation, a concern for the betterment of our world, and consistently high rankings of its schools and departments. The campus offers superior, high-value education for extraordinarily talented students from all walks of life, operational excellence, and a commitment to the competitiveness and prosperity of California and the nation.

About Princeton University

Princeton University is a vibrant community of teaching and research that stands in the nation's service and the service of humanity. Chartered in 1746, Princeton is the fourth-oldest college in the United States. Princeton is an independent, coeducational, nondenominational institution that provides undergraduate and graduate instruction in the arts and humanities, social sciences, natural sciences, and engineering.

About University of Chicago

The University of Chicago is a leading academic and research institution that has driven new ways of thinking since its founding in 1890. As an intellectual destination, the University draws scholars and students from around the world to its campuses and centers around the globe. The University provides a distinctive educational experience and research environment, empowering individuals to challenge conventional thinking and pursue field-defining research that produces new understanding and breakthroughs with global impact.

About Massachusetts Institute of Technology

The Massachusetts Institute of Technology is dedicated to advancing knowledge and educating students in science, technology, and other areas of scholarship that will best serve the nation and the world in the 21st century. The Institute has more than 1,000 faculty members and over 11,500 undergraduate and graduate students. MIT's commitment to innovation has led to a host of scientific breakthroughs and technological advances, in fields ranging from aeronautics to computing to cancer research.

About Carnegie Mellon University

Carnegie Mellon (cmu.edu) is a private, internationally ranked research university with programs in areas ranging from science, technology and business, to public policy, the humanities and the arts. More than 14,000 students in the university’s seven schools and colleges benefit from a small student-to-faculty ratio and an education characterized by its focus on creating and implementing solutions for real problems, interdisciplinary collaboration and innovation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005334/en/

Contacts

C3.ai Contact:
April Marks
Director of Public Relations
917-574-5512
pr@c3.ai

Microsoft Contact:
Microsoft Media Relations
WE Communications for Microsoft
(425) 638-7777
rrt@we-worldwide.com

UIUC Contact:
Robin Kaler
Associate Chancellor for Public Affairs
rkaler@illinois.edu
217-333-5050

University of California, Berkeley Contact:
Sarah Yang
Assistant Dean, Marketing & Communications
Berkeley Engineering
scyang@berkeley.edu

Princeton University Contact:
Ben Chang
Deputy Vice President, Communications
mediarelations@princeton.edu

University of Chicago Contact:
Rob Mitchum
Associate Director of Communications for Data Science and Computing
rmitchum@uchicago.edu
773-484-9890

MIT Contact:
Anne Stuart
Communications Officer in Electrical Engineering and Computer Science
astuart@mit.edu

Carnegie Mellon University Contact:
Jason Maderer
Sr. Director, Media Relations
412.268.1151
maderer@cmu.edu

Permalink : https://www.aetoswire.com/news/c3ai-microsoft-and-leading-universities-launch-c3ai-digital-transformation-institute-nbsp/en

ABB: COVID-19 Update



ZURICH-Monday 30 March 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- ABB is constantly monitoring the pandemic situation around COVID-19 (novel coronavirus). The health and safety of its employees, customers and partners remains the company’s number one priority and we are working hard to assess and mitigate any risks.

Guidance issued on February 5, 2020, did not include impacts due to the coronavirus, the effects of which were mainly limited to China at that time. We have subsequently experienced a decline in trading conditions due to the outbreak, further impacted by a weakening oil price.

The situation in China has stabilized following extensive government-led efforts in February and operations at ABB’s three main production hubs of Shanghai, Beijing and Xiamen have largely returned to normal. While weakened customer demand in China, our second largest market, will also impact the first quarter results, our China business has been improving recently. At the same time, COVID-19 has spread rapidly to the western hemisphere in March, resulting in governments and customers adopting containment measures that have material economic consequences across the globe.

Q1 2020 impact

Although it is not yet possible to determine the exact impact of COVID-19 on ABB’s first quarter results, ABB expects revenues to decline in all its businesses relative to a year ago, while orders are somewhat less impacted. The Robotics & Discrete Automation business, which was already facing significant end-market headwinds from the automotive sector, remains challenged, with first quarter orders and revenues both expected to decline by more than 20 percent year-on-year.

Operational EBITA margins are also expected to decline in all ABB’s businesses, burdened by lower volumes, partly offset by self-help efforts. Self-help initiatives are aided by the framework ABB already has in place to implement ABB’s Operating System (ABB-OS). At the same time, the company is significantly intensifying mitigation measures and actively reducing all non-essential costs, and all of ABB’s businesses are rigorously focused on serving their customers while sustaining cash flow.

2020 outlook

Each of our businesses are closely monitoring current and potential effects of the outbreak. Currently, the majority of ABB’s production facilities remain fully or partly operational and supply chain impacts have been minimal. However, the outbreak is expected to continue to have an impact globally, potentially creating disruption across production sites and further curtailing product demand, project and service activity.

In addition to short-cycle headwinds impacting all our businesses, we expect project business to be dampened by the weaker outlook for oil and gas capital expenditures and a fall-off in cruise ship activity. By contrast, transport projects look more resilient and the outlook for select high growth areas, such as data centers, remains robust. Systems and service activity is curtailed by restrictions to cross-border travel for specialized sales and service engineers.

ABB is accelerating and extending its mitigation measures ahead of what looks set to be a difficult second quarter, with a focus on adjusting capacity to meet reduced demand.

Given continued uncertainty, including the recent oil price decline, ABB is no longer providing financial guidance for full year 2020.

ABB continues to work toward the delivery of transformation milestones, including the divestment of Power Grids which is targeted for completion at the end of the second quarter.

Despite short-term disruptions, ABB is confident in the underlying resilience of its businesses and operating model, and that its short-term liquidity needs are well covered by the financial framework it has in place.

“I would like to take this opportunity during these extraordinary times to thank the whole ABB team for sticking together and handling this global pandemic with the highest level of professionalism,” said ABB CEO Björn Rosengren. “The health and safety of all stakeholders, above all our employees, remains our number one priority at this moment in time, while we also try our utmost to secure business continuity. We remain prepared for any scenario and will take strong action to mitigate the impact for our customers, shareholders and employees.”

“Furthermore, the Board of Directors and the Executive Committee of ABB have decided to voluntarily take an immediate 10 percent reduction in board compensation and salary for the duration of the crisis, with the view to extend this strong sign of solidarity to other senior management levels within the company. We must stay strong together for the whole of ABB and for our society. The money saved through the compensation and salary reductions will be donated by ABB towards efforts aimed at fighting the impacts of the Coronavirus crisis,” said the CEO.

“After many of my first meetings since joining ABB earlier this year, my impressions of the company and its people are very positive. ABB is a strong company, with a tremendous spirit and the right products and technology to drive the positive and sustainable development of the world in the future,” Rosengren added.

ABB plans for virtual communication

In light of the current situation around COVID-19, ABB plans to make more use of virtual media to facilitate continued communication with the financial community.

The following webcasts are currently scheduled:

Date
   


   

Topic
   


   

Host

April 28, 2020
   


   

Q1 Results: webcast
   


   

CEO, CFO

June 10, 2020
   


   

CEO first perspectives: webcast
   


   

CEO, CFO

Full details and additional events will be updated on www.abb.com/investorrelations when available.

ABB (ABBN: SIX Swiss Ex) is a technology leader that is driving the digital transformation of industries. With a history of innovation spanning more than 130 years, ABB has four, customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by the ABB Ability™ digital platform. ABB’s Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 144,000 employees.

This information is information that ABB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 6.45 a.m. CEST on March 30, 2020.

Important notice about forward-looking information

This press release includes forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance, including the future impact of the coronavirus, global economic conditions, and the economic conditions of the regions and industries that are major markets for ABB. These expectations, estimates and projections are generally identifiable by statements containing words such as “anticipates”, “expects,” “believes,” “estimates,” “plans”, “targets” or similar expressions. However, there are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this press release and which could affect our ability to achieve any or all of our stated targets. Many of the factors that could cause such differences are identified and discussed from time to time in ABB Ltd’s filings with the U.S. Securities and Exchange Commission, including its Annual Reports on Form 20-F. Although ABB Ltd believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200329005041/en/

Contacts

ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland

Media Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com

Investor Relations
Phone: +41 43 317 71 11
Email: investor.relations@ch.abb.com




Permalink : https://www.aetoswire.com/news/abb-covid-19-update-nbsp/en

XPRIZE Responds to COVID-19 by Uniting a Global Alliance of Innovators to Find Unconventional Solutions to Pandemic Threats

XPRIZE launches COVID-19 response platform, in collaboration with Anthem, and calls on the global community to unite, collaborate and share information to address immediate needs and find long-term, durable solutions to pandemic threats



LOS ANGELES -Sunday 29 March 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- XPRIZE, the world’s leader in designing and operating incentive competitions to solve humanity’s grand challenges, reveals the XPRIZE Pandemic Alliance, a global coalition that combines the power of collaboration, competition, shared innovation and radical thinking to accelerate solutions that can be applied to COVID-19 and future pandemics.

The XPRIZE Pandemic Alliance launched to address the immediate needs of the COVID-19 crisis by expanding visibility into solutions underway. This launch comes with an open call to arms to the world’s innovators, clinicians, researchers, data scientists, institutions, and experts to join the Alliance and share existing work and resources using covid19.xprize.org. This website will allow the global community to:

Participate in the latest breakthroughs, research and solutions in development;
Make asks of what they need and allow XPRIZE, the Alliance members and their vast network of supporters and partners to offer their resources to help enable and accelerate innovators to reach their goals faster.
In the immediate term, the Alliance will focus on areas such as accelerating solutions for remote care, provisioning personal protective equipment to the front lines, increasing access to testing, and improving food and medicine security for vulnerable populations, among others.

As part of this Alliance, researchers and scientists are invited to share and access data through the XPRIZE Data Collaborative, a unique platform for researchers and innovators to collaborate, share and learn from data in a broad spectrum of fields in their search for solutions. This trove of data aims to unlock new approaches to fighting pandemics and will serve as the backbone to the collective effort that will prepare us for additional pandemic spikes like COVID-19, or other viral threats.

As part of the XPRIZE Data Collaborative, our launch partner, Anthem, is taking the lead by providing vetted partners with access to one of the largest certified deidentified data set including years of longitudinal data for prior viral outbreaks (e.g., swine flu, avian flu, influenza).

XPRIZE will also host and launch a series of rapid data challenges in support of the Alliance’s initiatives, which may include developing an early warning system for future pandemics, predictive models for public health resource allocation, more efficient and affordable diagnostics, treatments and cures that can be rapidly reproduced, or others based on insights drawn from the collaborators.

Other notable global partners that have already agreed to join the Alliance include United States Department of Veterans Affairs, Ending Pandemics, Intel, Illumina, IEEE Standards Association, MIT Solve, C2 International, Cloudbreak Health, the Foundation Botnar, McGill University, Nvidia, the Patrick J. McGovern Foundation, PPE Coalition, and UCSD. XPRIZE is actively calling for more partners and members to join the Alliance.

“There are few times in recent history when one pandemic has affected so many people, but with all of us focused on one problem, it means impact and solutions will only be accelerated, and we’re excited to work with Anthem to amplify the potential of this platform in quickly enabling global talent to join the fight,” said XPRIZE CEO Anousheh Ansari. “At XPRIZE, we believe radical breakthroughs can come from anyone, anywhere, and our response to COVID-19 will help provide solutions when humanity’s most vulnerable need it most.”

“In this time of crisis, we see an opportunity to come together as a community via the powerful XPRIZE platform to address the most acute needs in the system today and to accelerate new solutions: from protecting our healthcare workers at the front lines and proactively taking care of the high risk populations to developing new approaches to diagnostics, therapy and vaccines,” said Rajeev Ronanki, Chief Digital Officer at Anthem.

“COVID-19 is not the first, nor the last pandemic humanity will face, and future pandemics could be far worse,” said XPRIZE Founder and Executive Chairman Peter H. Diamandis, MD. “For 25 years, XPRIZE has focused on solving global grand challenges, crowdsourcing solutions. The XPRIZE does this by inspiring innovators around the world to use exponential technologies to address problems in unbelievably short timeframes. The XPRIZE Pandemic Alliance will leverage data and human collaboration like never before to facilitate technological breakthroughs for the benefit of humankind.”

For more information, visit covid19.xprize.org.

Additional Quotes from XPRIZE Pandemic Alliance Partners:

“Technology can play a role in helping us to address the world’s largest challenges,” said Stacey Shulman, Chief Innovation Officer and VP, IOT Group, Intel. “Intel is partnering with XPRIZE to enable the larger community to find creative and impactful solutions for this global pandemic.”

“Never before have we had both the technology and collective will to develop a proactive global network for real time assessment and monitoring of infectious epidemics,” said Dr. Phil Febbo, Senior Vice President and Chief Medical Officer, Illumina. “We are pleased to be participating and helping to ensure that laboratories using our sequencers worldwide can integrate into a global community committed to preventing pandemics.”

“In response to the ongoing threat of COVID-19, Solve is focused on finding and supporting innovative solutions that address global health preparedness, early detection, and rapid response,” said Alex Amouyel, Executive Director at MIT Solve. “Better data sharing and analysis is one area that is critical in the effort to slow and track the spread of COVID-19 and future disease outbreaks—and Solve is pleased to join the XPRIZE Global Pandemic Data Alliance in that endeavor.”

"We are finding solutions and new innovations guided by lived experience, empathy, and a love of humanity and coming from unexpected and underexplored sources—makers/tinkerers who are also frontline health workers, student inventors, data scientists driven by social purpose," said Vilas Dhar, Trustee of the Patrick J. McGovern Foundation. "This Alliance creates a platform to engage those actors and many more in a shared quest to alleviate suffering and create a new paradigm for pandemic response."

XPRIZE

XPRIZE designs and operates multi-million-dollar, global competitions to accelerate the development of technological breakthroughs that benefit humanity. Active competitions include the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE, the $20 Million NRG COSIA Carbon XPRIZE, and the $10 Million Rainforest XPRIZE. For more information, visit xprize.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005217/en/

Contacts
Katherine Schelbert
XPRIZE
katherine.schelbert@xprize.org

Caden Kinard
XPRIZE
caden.kinard@xprize.org
(949) 280-0182


Permalink : https://www.aetoswire.com/news/xprize-responds-to-covid-19-by-uniting-a-global-alliance-of-innovators-to-find-unconventional-solutions-to-pandemic-threats/en

The Unprecedented Covid-19 Situation and its Impact on TV Advertising

Update brought to you by AMSI – A Choueiri Group Brand


Dubai, United Arab Emirates, -Sunday 29 March 2020 [ AETOS Wire ]

At a time when regional audiences are staying home more than ever before to support lockdown and self-isolation drives, MBC Group (The region’s leading broadcasters) have reported a significant surge in their overall performance, as well as their individual channels.

Insightful data findings from MBC Group indicate that behavioral changes have resulted in greater consumption of premium television content and entertainment. These are being shared to enable advertisers to reinforce and adapt their TV media investments and plans, while encouraging them to uplift their TV advertising initiatives in order to remain top-of-mind and to boost performance as well.

Arabian Media Services International (AMSI) is a part of Choueiri Group and operates as the Exclusive Media Representative for MBC Group.

Arabian Media Services International (AMSI)

As a part of Choueiri Group (The leading Media Representatives in the Middle East), Arabian Media Services International (AMSI) is the official representative of all MBC Group media, which offer leading programs to various social and demographic segments of the Middle East region. The MBC Group has indisputably established itself as the premier provider of TV entertainment content to the Arab World.

Contacts

Choueiri Group

Assad Jamil, +97144545454

ajamil.mr@choueirigroup.com

Permalink : https://www.aetoswire.com/news/the-unprecedented-covid-19-situation-and-its-impact-on-tv-advertising/en

ExThera’s Affinity Blood Filter Is Used to Treat COVID-19 Patients

MARTINEZ, Calif.-Sunday 29 March 2020 [ AETOS Wire ]

(BUSINESS WIRE)-- Treatment of COVID-19 with ExThera’s Seraph®100 Microbind® Affinity Blood Filter (Seraph 100) has begun in hospitals in Germany and Italy. Seraph 100 treatments of COVID-19 are also expected to begin soon in France and the USA.

Seraph 100 is the only ‘hemoperfusion device’ approved for the reduction of pathogens in blood. In recent EU clinical cases improved lung function and rapid reduction of drug-resistant bacterial pathogens occurred with Seraph 100 treatment. Stabilization of blood pressure has also been observed, including during COVID-19 treatment. Another potential benefit of Seraph 100 treatment of COVID-19 is reduction in bloodborne virus/RNA, and the simultaneous treatment of bacterial and fungal ‘secondary infections’.

Clinical results and virus binding studies suggested that Seraph 100 treatment should help in the treatment of COVID-19, and in future epidemics, before vaccines are available. More clinical results are needed to confirm patient benefit in COVID-19, but lab studies with cytokines and other pathogens have accurately predicted Seraph 100 clinical results in other bloodstream infections.

One consideration is whether SARS-CoV-2 is present in the bloodstream of infected patients in measurable concentrations, and if so, at what stage of the infection. Very recent publications and clinician feedback confirm the presence of the virus (RNA) in the blood of critically ill COVID-19 patients. The measured binding capacity of a single Seraph 100 filter (about the size of a 12-ounce soda can) is huge in comparison to the amount of virus present in the bloodstream of critically-ill patients.

Lakhmir S. Chawla, MD, Chair of ExThera’s Scientific Advisory Board added, “In respiratory diseases caused by viruses, the onset of viremia (virus in the bloodstream) typically heralds severe disease. Reducing viral levels of COVID-19 may allow the body’s immune system to combat the deadly pathogen.”

President and CEO of ExThera Medical, Robert Ward NAE stated, “We are very pleased to confirm the feasibility of Seraph 100 treatment of COVID-19. Since Seraph 100 treatments have also consistently produced improved oxygenation/lung function, we believe that this feature together with virus reduction may be a useful combination for treating COVID-19, while simultaneously treating the dangerous secondary infections that can occur in COVID-19 patients.”

Seraph 100 has CE Mark approval in the European Union but is not currently approved by the FDA for use in the United States. ExThera has received clinician interest in individual emergency use of Seraph 100 in the USA and we expect COVID-19 treatments to begin here soon, when they meet the criteria outlined in the FDA Guidance. ExThera will report on ongoing EU COVID-19 cases and related case studies as soon as they are available, while adhering to HIPAA and GDPR requirements for patient confidentiality. Related peer-reviewed publications are in preparation or in press.

“We are excited about adding SARS-CoV-2 to the long list of bloodborne pathogens that Seraph 100 can target,” commented Keith McCrea, PhD. and Chief Science Officer of ExThera Medical. “This can open up a new treatment modality for this and future emerging diseases for which there are few if any treatments.” Seraph 100’s very broad-spectrum capability is based on its large biomimetic blood-contacting surface that imitates the binding sites disease-causing pathogens target once they find their way into the bloodstream.

The Seraph 100 blood filter provides a needed option for treating life-threatening bloodstream infections using new technology. Whereas first-generation hemoperfusion devices remove only molecules, Seraph 100 also quickly lowers the concentration of bacteria, viruses, and fungi in whole blood. Seraph 100 is able to significantly reduce the bloodstream concentration of both drug-susceptible and drug-resistant pathogens, providing a long-awaited adjunctive therapy that addresses the severe problem of drug-resistance, and new and future bacterial, fungal and viral threats like COVID-19.

Professor Jan Kielstein, Director of Medical Clinic V, Academic Teaching Hospital Braunschweig, Germany who has performed many Seraph 100 treatments recently said, "When a pathogen like SARS-CoV-2 comes out of Pandora's Box we have to think outside of the box for a countermeasure. Seraph 100 is a disruptive technology that had been shown to eliminate infectious agents from the blood without side effects. Extracorporeal treatment with the Seraph 100 could offer an added benefit to critically ill patients with severe COVID-19."

Seraph 100 received CE Mark approval for the broad indication of pathogen reduction during bloodstream infections in adjunction with antibiotic therapy. Seraph 100 distributors in the EU include Heinz Meise GmbH in Germany, Burke & Burke in Italy, and TOP Medical in the Benelux countries. Distributors have recently been named in several other regions. Working with Gorta, Ireland’s oldest NGO, ExThera has also entered a public-private partnership designed to strengthen public health systems in developing countries by making world-class medical devices available at affordable prices.

About the Seraph® 100 (Seraph) Microbind® Affinity Blood Filter

As a patient's blood flows through the Seraph filter, it passes over tiny beads with receptors that mimic the receptors on human cells that pathogens target when they invade the body. Harmful substances are quickly captured and adsorbed onto the surface of the beads and are thereby removed from the bloodstream. Seraph does not add anything to the blood, which is returned to the patient with blood cells and proteins intact. Seraph targets the pathogens that cause the infection, while it also binds and removes harmful substances generated by the pathogen and by the body’s response to the infection. Seraph’s adsorption media (the beads) constitute a flexible platform that uses immobilized (chemically bonded) heparin for its well-established blood compatibility and its unique ability to bind bacteria, viruses, fungi, and important sepsis mediators reported to contribute to organ failure during sepsis. The ‘anti-thrombogenic’ heparin media can be combined with other ExThera-proprietary media to tailor the capability of future Seraph products for the treatment of specific diseases, or to further broaden Seraph’s capability.

About ExThera Medical

Based in Martinez, California, near San Francisco, and in Vaals, The Netherlands, ExThera Medical Corporation is a privately held medical device company developing innovative blood filters capable of removing a broad range of harmful substances from the blood. The company develops therapeutic products to treat patients in the hospital or clinic, during epidemics, or on the battlefield. Led by an accomplished management team with decades-long experience in the development and manufacture of blood-contacting implants, devices, and enabling biomaterials technology, the company has strong patent protection and a growing body of data from independent laboratory studies, from its participation in DARPA’s Dialysis-Like Therapeutics program, and from successful clinical use in the EU.

For more information and an instructive video please visit our website: www.extheramedical.com

Seraph 100 is not currently approved for use by the US FDA

Disclaimer: All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005174/en/

Contacts
Galit Gelman & Mandy Van Haaren
Media@extheramedical.com




Permalink : https://www.aetoswire.com/news/extherarsquos-affinity-blood-filter-is-used-to-treat-covid-19-patients/en